Adjuvant Therapy of Primary Breast Cancer: Closing Summary
作者： J. H. Glick , R. D. Gelber , A. Goldhirsch , H.-J. Senn
DOI: 10.1007/978-3-642-84745-5_38
关键词:
摘要: Adjuvant therapy for stage I and II breast cancer remains in evolution as new data emerge from controlled randomized trials the overview analysis by Early Breast Cancer Trialists’ Collaborative Group [4] (reprinted part this volume; referred to below Overview). The Fourth International Conference on Therapy of Primary Cancer, held St. Gallen, Switzerland, February, 1992, brought together experts all over world present their most recent discuss remaining challenges that confront both clinicians basic scientists.
springer.com
sci-hub.st 参考文章(4)
Early Breast Cancer Trialist's Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. The Lancet. ,(1992) , 10.1016/0140-6736(92)90997-H
P P Rosen, S Groshen, P E Saigo, D W Kinne, S Hellman, Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. Journal of Clinical Oncology. ,vol. 7, pp. 1239- 1251 ,(1989) , 10.1200/JCO.1989.7.9.1239
C. Brambilla, S. Zurrida, 4th international conference on adjuvant therapy of primary breast cancer — St Gallen, Switzerland, 26–29 February 1992 The Breast. ,vol. 1, pp. 141- 142 ,(1992) , 10.1016/0960-9776(92)90164-W
J. H. Glick, Meeting Highlights: Adjuvant Therapy for Breast Cancer Journal of the National Cancer Institute. ,vol. 80, pp. 471- 475 ,(1988) , 10.1093/JNCI/80.7.471